Patritumab Deruxtecan vs Ruzaltatug rezetecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline

Patritumab Deruxtecan

Developed by Daiichi Sankyo and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT05865990 · Phase 2 · completed

The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: August 2029 · NCT07286149 (registry estimate)

Reported efficacy

Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2. (From baseline to the date of first documented progression, death from any cause, or treatment discontinuation from any reason, whichever came first, assessed up to 12 months); Efficacy: Overall survival (OS) rate at 3 months in cohort 3. (From baseline up to 3 months): LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) (met)

Result source: NCT05865990

Ruzaltatug rezetecan

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06671379 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPatritumab DeruxtecanRuzaltatug rezetecan
PFS, median—Trial running · NCT05338970—Trial running · NCT06671379
OS, median—Trial running · NCT05338970—Trial running · NCT06671379
ORR—Trial running · NCT05338970—Trial running · NCT06671379
Duration of response, median—Trial running · NCT05338970—Trial running · NCT06671379

PFS, median

Patritumab Deruxtecan
—Trial running · NCT05338970
Ruzaltatug rezetecan
—Trial running · NCT06671379

OS, median

Patritumab Deruxtecan
—Trial running · NCT05338970
Ruzaltatug rezetecan
—Trial running · NCT06671379

ORR

Patritumab Deruxtecan
—Trial running · NCT05338970
Ruzaltatug rezetecan
—Trial running · NCT06671379

Duration of response, median

Patritumab Deruxtecan
—Trial running · NCT05338970
Ruzaltatug rezetecan
—Trial running · NCT06671379
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ruzaltatug rezetecan: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Patritumab Deruxtecan
LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) NCT05865990 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Patritumab Deruxtecan's landscape · Ruzaltatug rezetecan's landscape